Clinical Research Directory

Inclusion Criteria: * Male or female patients aged \>18 years * Greater than 3 months from first hemorrhagic or ischemic stroke (subacute to chronic), confirmed through neuroimaging (CT or MRI). * Fatigue severity score average \>4 (severe fatigue) * Willingness to remain stable on pharmacologic therapy through the duration of the study. * Availability of a caregiver, family member, or friend to be present during the administration of the tDCS intervention. Exclusion Criteria: * Metal in the head (except mouth) or implanted cranial or thoracic devices (i.e. pacemaker, DBS stimulator) * History of seizure * History of moderate to severe traumatic brain injury * A score of 10 or more on the PHQ-9 or GAD-7 scale, suggestive of moderate to severe depression/anxiety. * A score of less than 21 on the MoCA suggesting major neurocognitive disorder. * Signs of skin rash, infection, or laceration in the supraorbital region where the tDCS will be applied. * Inability to provide informed consent * Other major neurological, medical, or psychiatric illnesses that could confound results in the opinion of the site investigator.